Arcturus Therapeutics reported a decrease in total assets from $271.1 million at the end of 2025 to $215.3 million as of September 30, 2026, primarily driven by a reduction in cash and cash equivalents. The company's forward-looking statements highlight the termination of the CSL Collaboration Agreement and plans to advance its therapeutics pipeline, including ARCT-810 and ARCT-032, independently or with other partners.
Arcturus Therapeutics reported Q3 2026 financial results, ending the period with $281.3 million in cash and equivalents. The company highlighted pipeline progress, including the completion of the myNEO acquisition and plans to complete enrollment for its ARCT-032 Phase 2 cystic fibrosis study by year-end 2026.
Term
Q3 2026
“The third quarter marked a pivotal step forward for our liver therapeutics franchise, with encouraging ARCT-810 Phase 2 results and the introduction of LUNAR 2.0™, our next-generation mRNA delivery platform, which demonstrated a 38-fold improvement over the key lipid in ARCT-810 in non-human primates.”